University Health Network, Toronto Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3

Organization Overview

First Clinical Trial
2014
NCT02034266
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Eduardo Ng | Jas Chahal | Marcelo Cypel

Active Ingredients

Drugs in Phase 3 Trials (1)

immune globulin (human) (Gamastan) (1 trial)

Drugs in Phase 2 Trials (2)

autologous mesenchymal stem cells (1 trial)

omega-3 fatty acids (Omacor) (1 trial)

Drugs in Phase 1 Trials (2)

sofosbuvir (sovaldi) (1 trial)

velpatasvir (Epclusa) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 1 (Phase 2)

Hepatitis (Phase 1)

Hepatitis A (Phase 1)

Hepatitis C (Phase 1)

Osteoarthritis (Phase 2)

Osteoarthritis, Knee (Phase 2)

Polyneuropathies (Phase 3)

Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 5